Relmada Therapeutics, Inc.

NasdaqGS:RLMD Stock Report

Market Cap: US$11.9m

Relmada Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:RLMD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 Sep 24BuyUS$149,701Maged ShenoudaIndividual53,432US$2.95
11 Sep 24BuyUS$395,115Sergio TraversaIndividual140,000US$2.99
09 Sep 24BuyUS$64,750Paul KellyIndividual25,000US$2.59
09 Sep 24BuyUS$33,280Charles CasamentoIndividual13,000US$2.56

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RLMD?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds2,050,0006.18%
Individual Insiders2,623,5547.9%
Institutions8,431,67725.4%
General Public20,086,39160.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 36.61% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.18%
Squadron Capital Management Llc
2,050,000US$732.3k0%no data
5.72%
Kevin Kotler
1,899,930US$678.7k0%no data
3.92%
Franklin Resources, Inc.
1,302,151US$465.1k0%no data
3.79%
The Vanguard Group, Inc.
1,256,705US$448.9k0%no data
3.7%
Acadian Asset Management LLC
1,227,928US$438.6k3.5%no data
1.71%
BlackRock, Inc.
566,905US$202.5k-4.45%no data
1.49%
Palo Alto Investors LP
495,146US$176.9k-32.4%0.03%
1.16%
Sergio Traversa
384,024US$137.2k0%no data
0.91%
Geode Capital Management, LLC
302,838US$108.2k-0.55%no data
0.68%
Deutsche Asset & Wealth Management
224,846US$80.3k0%no data
0.65%
UBS Asset Management AG
215,140US$76.8k70.2%no data
0.64%
Paul Kelly
212,295US$75.8k0%no data
0.63%
AdvisorShares Investments, LLC
210,068US$75.0k207%0.01%
0.62%
Bank of America Corporation, Asset Management Arm
206,657US$73.8k0%no data
0.61%
Tang Capital Management, LLC
200,825US$71.7k295%no data
0.6%
Two Sigma Advisers, LP
198,900US$71.0k-18%no data
0.5%
Renaissance Technologies LLC
164,513US$58.8k535%no data
0.49%
Parsons Capital Management, Inc.
163,336US$58.3k0%no data
0.49%
RBF Capital LLC
163,261US$58.3k-1.34%no data
0.44%
Barclays PLC Private Banking & Investment Banking Investment
145,999US$52.2k0%no data
0.38%
Two Sigma Investments, LP
127,579US$45.6k-33.3%no data
0.38%
GSA Capital Partners LLP
124,773US$44.6k15.1%no data
0.32%
State Street Global Advisors, Inc.
106,735US$38.1k7.56%no data
0.31%
Group One Trading LP, Asset Management Arm
102,087US$36.5k3.18%no data
0.3%
Rosalind Advisors, Inc.
100,000US$35.7k0%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 20:11
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Relmada Therapeutics, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maxim JacobsEdison Investment Research
Lin TsaiJefferies LLC
Marc GoodmanLeerink Partners LLC